Compare USLM & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USLM | NVCR |
|---|---|---|
| Founded | 1948 | 2000 |
| Country | United States | Switzerland |
| Employees | 346 | N/A |
| Industry | Other Metals and Minerals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.0B |
| IPO Year | 1994 | 2015 |
| Metric | USLM | NVCR |
|---|---|---|
| Price | $117.16 | $15.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $138.00 | $28.08 |
| AVG Volume (30 Days) | 106.2K | ★ 1.1M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | ★ 23.22 | 21.79 |
| EPS | ★ 2.26 | N/A |
| Revenue | $144,435,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $27.25 | $7.72 |
| Revenue Next Year | $13.76 | $6.74 |
| P/E Ratio | $51.16 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $96.27 | $9.82 |
| 52 Week High | $141.44 | $21.45 |
| Indicator | USLM | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 37.66 |
| Support Level | $102.60 | $14.84 |
| Resistance Level | $121.49 | $18.43 |
| Average True Range (ATR) | 3.29 | 0.80 |
| MACD | -0.70 | -0.27 |
| Stochastic Oscillator | 25.04 | 8.31 |
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. The company supplies its products predominantly to the construction including highway, road, and building contractors, industrial including paper and glass manufacturers, environmental including municipal sanitation and water treatment facilities and flue gas treatment processes, metals including steel producers, oil and gas services, roof shingle manufacturers and agriculture including poultry industries. The company operates through its Lime and Limestone Operations segment.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.